Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Withdrawn 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Lymphoma 5Leukemia, Myeloid, Acute 4Recurrence 3Lymphoma, Non-Hodgkin 3Lymphoma, Large B-Cell, Diffuse 3Ovarian Neoplasms 2Oligodendroglioma 2Lymphoma, B-Cell 2Leukemia 2Hodgkin Disease 2Astrocytoma 2Wilms Tumor 1Testicular Neoplasms 1Testicular Germ Cell Tumor 1Teratoma 1Spinal Cord Neoplasms 1Small Cell Lung Carcinoma 1Sarcoma 1Rhabdoid Tumor 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Ovarian Germ Cell Cancer 1Osteosarcoma 1Optic Nerve Glioma 1Neuroectodermal Tumors, Primitive, Peripheral 1Neuroblastoma 1Nephroma, Mesoblastic 1Myelodysplastic Syndromes 1Multiple Myeloma 1Metastatic NUT Carcinoma 1Medulloblastoma 1

Interventions

molibresib 1etoposide phosphate 1Platinum 1Etoposide 1Cisplatin 11,2-diaminocyclohexaneplatinum II citrate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Metastatic NUT Carcinoma × etoposide phosphate × Clear all
NCT04116359 2020-09-28

Testing of the Addition of a New Anti-cancer Drug, Molibresib, to Chemotherapy Treatment (Etoposide and Cisplatin) for Patients With NUT Carcinoma

National Cancer Institute (NCI)

Phase 1/2 Withdrawn

Metastatic NUT Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡